IONIS PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
ITEM 5.
OTHER INFORMATION
Trading Plans
During the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** "Non-Rule 10b5-1 trading arrangement" as defined in item 408(c) of Regulation S-K under the Exchange Act.
| Trading Arrangement · Total Shares | ||||||
|---|---|---|---|---|---|---|
| Name · Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · to be Sold · Expiration Date | ||||||
| Eric Swayze | Executive Vice President, Research | Termination | March 6, 2026 | X | 177,770 | The earlier to occur of (i) December 31, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Holly Kordasiewicz | Executive Vice President, Chief Development Officer | Adoption | March 13, 2026 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) May 31, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Eric Swayze | Executive Vice President, Research | Adoption | March 6, 2026 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) December 31, 2030, and (ii) Upon the execution of all instructions provided in the plan |
| Frank Bennett | Executive Vice President, Chief Scientific Officer | Adoption | March 31, 2026 | X | 67,386 | The earlier to occur of (i) July 5, 2027, and (ii) Upon the execution of all instructions provided in the plan |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.